Xenetic Biosciences Statistics
Share Statistics
Xenetic Biosciences has 1.54M shares outstanding. The number of shares has increased by 0.09% in one year.
| Shares Outstanding | 1.54M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.09% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 1.25M |
| Failed to Deliver (FTD) Shares | 4 |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
The latest short interest is 14.83K, so 0.96% of the outstanding shares have been sold short.
| Short Interest | 14.83K |
| Short % of Shares Out | 0.96% |
| Short % of Float | 1.18% |
| Short Ratio (days to cover) | 0.77 |
Valuation Ratios
The PE ratio is -1.28 and the forward PE ratio is -5.76.
| PE Ratio | -1.28 |
| Forward PE | -5.76 |
| PS Ratio | 2.08 |
| Forward PS | 3.4 |
| PB Ratio | 0.54 |
| P/FCF Ratio | -1.28 |
| PEG Ratio | n/a |
Enterprise Valuation
Xenetic Biosciences Inc. has an Enterprise Value (EV) of 5.27M.
| EV / Earnings | -1.28 |
| EV / Sales | 2.08 |
| EV / EBITDA | -1.17 |
| EV / EBIT | -1.17 |
| EV / FCF | -1.28 |
Financial Position
The company has a current ratio of 11.84, with a Debt / Equity ratio of 0.
| Current Ratio | 11.84 |
| Quick Ratio | 11.84 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.42% and return on capital (ROIC) is -46.1%.
| Return on Equity (ROE) | -0.42% |
| Return on Assets (ROA) | -0.39% |
| Return on Capital (ROIC) | -46.1% |
| Revenue Per Employee | 635.00K |
| Profits Per Employee | -1.03M |
| Employee Count | 4 |
| Asset Turnover | 0.24 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 12.64% in the last 52 weeks. The beta is 2.26, so Xenetic Biosciences 's price volatility has been higher than the market average.
| Beta | 2.26 |
| 52-Week Price Change | 12.64% |
| 50-Day Moving Average | 3.99 |
| 200-Day Moving Average | 4.01 |
| Relative Strength Index (RSI) | 45.31 |
| Average Volume (20 Days) | 24.86K |
Income Statement
In the last 12 months, Xenetic Biosciences had revenue of $2.54M and earned -$4.13M in profits. Earnings per share was $-2.71.
| Revenue | 2.54M |
| Gross Profit | 2.54M |
| Operating Income | -4.52M |
| Net Income | -4.13M |
| EBITDA | -4.52M |
| EBIT | -4.52M |
| Earnings Per Share (EPS) | -2.71 |
Balance Sheet
The company has $8.98M in cash and $0 in debt, giving a net cash position of $8.98M.
| Cash & Cash Equivalents | 8.98M |
| Total Debt | 0 |
| Net Cash | 8.98M |
| Retained Earnings | -193.23M |
| Total Assets | 8.05M |
| Working Capital | 6.02M |
Cash Flow
In the last 12 months, operating cash flow was -$4.11M and capital expenditures $0, giving a free cash flow of -$4.11M.
| Operating Cash Flow | -4.11M |
| Capital Expenditures | 0 |
| Free Cash Flow | -4.11M |
| FCF Per Share | -2.69 |
Margins
Gross margin is 100%, with operating and profit margins of -177.79% and -162.78%.
| Gross Margin | 100% |
| Operating Margin | -177.79% |
| Pretax Margin | -162.78% |
| Profit Margin | -162.78% |
| EBITDA Margin | -177.79% |
| EBIT Margin | -177.79% |
| FCF Margin | -161.98% |
Dividends & Yields
XBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -67.58% |
| FCF Yield | -66.53% |
Analyst Forecast
Currently there are no analyst rating for XBIO.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on May 15, 2023. It was a backward split with a ratio of 1:10.
| Last Split Date | May 15, 2023 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -30.92 |
| Piotroski F-Score | 2 |